{"schema_version":"1.0","type":"article","title":"明星心臟藥銷售減半，諾華的新藥接棒來得及嗎？","url":"https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation.md","lang":"zh-Hant","date":"2026-10-06","publish_at":"2026-10-06T20:00:00+08:00","updated_at":"2026-10-06","category":"商業分析系列","topic":"商業分析系列","tags":["Novartis","諾華","Entresto","Avidity","del-desiran","pelacarsen","remibrutinib","資本配置","新藥授權","專利到期"],"summary":"諾華（Novartis）的心臟藥Entresto在2026年第二季美元銷售年減50%；進入9月，原列在未來兩年申請規劃中的pelacarsen與del-desiran，又先後公布第三期主要終點未達。收入侵蝕已反映在財報，兩項候選藥的申請前提卻需要重估。","key_points":[],"facts":[],"sections":[],"references":[{"title":"Novartis Financial Results Q2 2026 — Media Release","source":"","date":"","url":""},{"title":"https://www.novartis.com/sites/novartis_com/files/q2-2026-media-release-en.pdf","source":"","date":"","url":"https://www.novartis.com/sites/novartis_com/files/q2-2026-media-release-en.pdf"},{"title":"Novartis Q2 2026 Condensed Interim Financial Report — Supplementary Data","source":"","date":"","url":""},{"title":"https://www.novartis.com/sites/novartis_com/files/q2-2026-interim-financial-report-en.pdf","source":"","date":"","url":"https://www.novartis.com/sites/novartis_com/files/q2-2026-interim-financial-report-en.pdf"},{"title":"Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD","source":"","date":"","url":""},{"title":"https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd","source":"","date":"","url":"https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd"},{"title":"Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy","source":"","date":"","url":""},{"title":"https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy","source":"","date":"","url":"https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avidity-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xrna-strategy"},{"title":"Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1","source":"","date":"","url":""},{"title":"https://www.novartis.com/news/media-releases/novartis-provides-update-delpacibart-etedesiran-del-desiran-phase-iii-harbor-study-treatment-myotonic-dystrophy-type-1-dm1","source":"","date":"","url":"https://www.novartis.com/news/media-releases/novartis-provides-update-delpacibart-etedesiran-del-desiran-phase-iii-harbor-study-treatment-myotonic-dystrophy-type-1-dm1"},{"title":"Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials","source":"","date":"","url":""},{"title":"https://www.novartis.com/news/media-releases/novartis-remibrutinib-high-efficacy-oral-btk-inhibitor-significantly-reduces-relapse-rates-and-shows-favorable-safety-profile-phase-iii-rms-trials","source":"","date":"","url":"https://www.novartis.com/news/media-releases/novartis-remibrutinib-high-efficacy-oral-btk-inhibitor-significantly-reduces-relapse-rates-and-shows-favorable-safety-profile-phase-iii-rms-trials"},{"title":"Novartis Q2 2026 Investor Presentation","source":"","date":"","url":""},{"title":"https://www.novartis.com/sites/novartis_com/files/q2-2026-investor-presentation.pdf","source":"","date":"","url":"https://www.novartis.com/sites/novartis_com/files/q2-2026-investor-presentation.pdf"},{"title":"Novartis Financial Results — Q3 2026","source":"","date":"","url":""},{"title":"https://www.novartis.com/events/novartis-financial-results-q3-2026","source":"","date":"","url":"https://www.novartis.com/events/novartis-financial-results-q3-2026"},{"title":"An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1","source":"","date":"","url":""},{"title":"https://pubmed.ncbi.nlm.nih.gov/41707138/","source":"","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/41707138/"}],"images":[{"alt":"上半以心臟、乳癌細胞與神經纖維圖示分別呈現Entresto、Kisqali及Kesimpta；Entresto旁標2026年第二季銷售以美元計年減50%。下半標示「候選藥／新適應症」，以細虛線連接臨床驗證、監管審查及市場採用。","url":"https://drugnews.com.tw/assets/articles/novartis-growth-succession-capital-allocation/FIG01_ZH_R2.png"},{"alt":"上半的可溶性抗體攜帶小干擾RNA，一個Fab末端接近肌肉細胞膜上TfR1的胞外端，Fc朝向膜外空間。胞內小干擾RNA與有毒DMPK訊息RNA分開，經中性機制節點連到RNA片段；虛線表示作用設計。下半另以手部量測與研究文件呈現54週HARBOR及主要終點未達。","url":"https://drugnews.com.tw/assets/articles/novartis-growth-succession-capital-allocation/FIG02_ZH_v2.png"},{"alt":"上半以肝細胞RNA、心血管圖示及研究文件呈現pelacarsen，標示主要終點未達。下半以B細胞內、細胞核外的BTK節點及神經纖維呈現remibrutinib，抑制符號止於BTK，結果標示年化復發率終點達標。兩條路徑分別對應各自研究。","url":"https://drugnews.com.tw/assets/articles/novartis-growth-succession-capital-allocation/FIG03_ZH_v2.png"},{"alt":"三個獨立區域呈現Avidity收購、後續研發與減值評估。收購區標2026年2月27日完成、約120億美元現金對價及平台與多項計畫；研發與減值各以研究或估值文件表示另行決策。下方連向下一筆資金決策，並區分減值評估與再次支付收購款。","url":"https://drugnews.com.tw/assets/articles/novartis-growth-succession-capital-allocation/FIG04_ZH_v2.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/novartis-growth-succession-capital-allocation/FIG01_ZH_R2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-06）。明星心臟藥銷售減半，諾華的新藥接棒來得及嗎？。https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-10-06-novartis-growth-succession-capital-allocation-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}